Swedbank AB Sells 32,800 Shares of Insulet Corporation $PODD

Swedbank AB lowered its position in shares of Insulet Corporation (NASDAQ:PODD) by 38.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,188 shares of the medical instruments supplier’s stock after selling 32,800 shares during the quarter. Swedbank AB’s holdings in Insulet were worth $11,161,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PODD. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet in the fourth quarter worth about $26,000. DV Equities LLC purchased a new stake in Insulet in the fourth quarter worth about $28,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the fourth quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Insulet during the fourth quarter valued at approximately $29,000.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.36% of the company’s stock.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
• Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
• Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

Analyst Upgrades and Downgrades

PODD has been the topic of a number of analyst reports. Citigroup boosted their price target on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday. UBS Group set a $219.00 price objective on Insulet in a research report on Thursday, June 11th. Oppenheimer lowered their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Piper Sandler dropped their target price on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, Jefferies Financial Group cut their target price on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $237.08.

Insulet Stock Up 1.9%

Shares of NASDAQ PODD traded up $2.99 during midday trading on Friday, hitting $161.28. The stock had a trading volume of 723,321 shares, compared to its average volume of 1,357,711. The business’s 50 day moving average is $152.93 and its 200-day moving average is $211.33. The company has a market cap of $11.17 billion, a P/E ratio of 37.51, a PEG ratio of 1.10 and a beta of 1.11. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the company posted $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts predict that Insulet Corporation will post 6.46 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.